gip glp 1 agonist tirzepatide Understand GLP-1/GIP Dual and Its Effect on Current Weight Loss Therapy The GLP-1 family, explained for

Such an approach aligns with modern public health priorities, offering the potential to reduce colorectal cancer incidence while simultaneously addressing obesity, diabetes, and cardiovascular disease

In November 2023, the rate of discontinuations due to medication availability peaked at 14.6%

For context, semaglutide alone achieved 14.9% weight loss in the same trial

Diabetes Obes Metab 22(12):24872492 Verma S, Bhatta M, Davies M, Deanfield JE, Garvey WT, Jensen C, et al (2023) Effects of once-weekly semaglutide 2.4 mg on C-reactive protein in adults with overweight or obesity (STEP 1, 2, and 3): Exploratory analyses of three randomised, double-blind, placebo-controlled, phase 3 trials

April 15, 2026

Zhang L, Zhang L, Li L, Hlscher C